As we continue to navigate the ever-evolving landscape of the COVID-19 pandemic, a new question arises: Should individuals opt for an immediate booster shot or patiently wait for the upcoming fall booster? The emergence of new variants, evolving vaccine recommendations, and shifting infection rates have given rise to this unique dilemma. In this blog, we’ll delve into the factors to consider when making this decision and provide insights to help you make an informed choice.
The last week of June saw approximately 6,000 COVID-related hospitalizations in the United States. By the last week of July, this figure had risen to 9,000—an unmistakable upward trend, albeit from historically low levels. The World Health Organization (WHO) also reports a global surge. This serves as a stark reminder that despite declarations from the World Health Organization and the Centers for Disease Control and Prevention (CDC) that the COVID “emergency” has subsided, the pandemic is far from concluded.
Dr. Amesh Adalja, an infectious disease specialist and senior scholar at the Johns Hopkins Center for Health Security, interprets the signs as indicative of an expected increase based on patterns observed in previous summers. This emphasizes the necessity for heightened caution.
These developments elicit concerns, particularly for those at higher risk or individuals planning late summer travels, returning kids to school, or in close contact with vulnerable populations. This prompts a pressing question: What actions should be taken concerning booster shots?
As of reference, the CDC initially advised bivalent COVID-19 vaccine boosters in September 2022 for individuals aged 12 and above. This specialized vaccine triggers immune responses against two virus variants, effectively guarding against the original virus and omicron variants BA.4 and BA.5.
In April 2023, this recommendation was extended to include children as young as six months. Furthermore, the guidance now permits, rather than explicitly recommends, a second bivalent booster dose for those 65 and older, granted an interval of at least four months since their previous shot. Dr. Adalja explains that the four-month gap is crucial to prevent interference with the immune response, avoiding reduced effectiveness due to overly close succession.
Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau, notes that the four-month minimum is a theoretical construct, lacking a concrete empirical foundation. Individuals with compromised immune systems were also greenlit for boosters, coupled with guidance to consult doctors regarding additional doses every two months. This approach acknowledges potential weaker vaccine reactions among immunocompromised individuals.
Anticipating the coming fall, Pfizer and Moderna are developing an upgraded booster more attuned to prevailing COVID-19 strains. Anchored in guidance from their vaccine advisory committee, these pharmaceutical companies are crafting vaccines using XBB 1.5—a subvariant of the omicron variant driving a growing number of infections. Although an exact release date remains uncertain, these revised boosters are slated for availability in the fall.
Presently, existing boosters offer a robust defense against severe disease but might not completely preclude infection. Ongoing variant evolution, mainly in the spike protein on the virus’s surface, highlights the need for updated vaccines capable of more accurately targeting these variations and thwarting their cellular infiltration.
Following FDA approval of the new vaccine iteration, expected shortly, the Centers for Disease Control and Prevention will determine the U.S. distribution strategy. This prompts the question: Should one opt for a booster now, wait until fall, or even consider a double dose?
Dr. Abraar Karan, an infectious disease fellow at Stanford, notes that timing remains complex, especially given the dominant EG.5 variant in the U.S. Neither the present booster nor the upcoming one precisely matches this variant, although the forthcoming booster is projected to exhibit greater alignment. If contemplating a pre-fall booster, Dr. Karan advises discussing individual circumstances with a medical professional, given the nuanced benefits.
Dr. Preeti Malani, an infectious disease specialist from the University of Michigan School of Medicine, generally echoes this sentiment, suggesting that waiting for the new vaccine aligning with current variants offers a more favorable match. However, certain specific scenarios might necessitate the bivalent vaccine sooner rather than later. For most, adopting familiar preventive measures, such as wearing masks in crowded indoor settings, while waiting is recommended.
Dr. Paul Offit, who leads the Vaccine Education Center at Children’s Hospital of Philadelphia and is a member of the FDA’s advisory committee, advocates for immediate booster consideration among high-risk individuals. He attributes the current booster’s efficacy against severe disease to cytotoxic T cells, which limit virus exposure. This cell type plays a vital role in curbing hospitalization and mortality rates.
Questions have arisen regarding the implications of numerous COVID-19 shots. Dr. Adalja raises concerns about the potential suppression of immune responses from prior vaccination sequences, potentially compromising the effectiveness of new boosters.
Testing’s importance remains steadfast. Dr. Karan highlights the value of at-home tests in isolating infections, protecting vulnerable individuals, and aiding appropriate treatment. While no longer government-funded, these tests are available for $15 to $30 per kit and have extended expiration dates, a crucial aspect to check.
Recent U.S. hospitalization data reiterates that while the “emergency” label might have shifted, the pandemic’s impact persists. A global uptick mirrors these trends, prompting a reevaluation of booster efficacy and the need for sustained preventive measures.
Despite vaccination campaigns, experts emphasize the significance of sustained caution. Dr. Amesh Adalja underscores the likelihood of an uptick, paralleling previous summers. The current booster addresses variants BA.4 and BA.5 effectively against severe disease but might not entirely prevent infection. An eagerly awaited more responsive booster targeting the XBB 1.5 subvariant of omicron is on the horizon, pending FDA approval.
Navigating booster decisions involves complexity. Dr. Abraar Karan recommends individualized consultations with healthcare providers. Dr. Preeti Malani advises patience for the forthcoming booster attuned to current strains.
Dr. Paul Offit recommends immediate consideration for high-risk groups. He credits immune memory cells for reducing severe disease impact. To manage COVID’s evolving dynamics, accessible testing aids in symptom identification and guiding treatment decisions.
With schools reopening, Dr. Adam Ratner from NYU Langone Health highlights the necessity of keeping children’s boosters up-to-date. Open communication and risk assessment within families remain pivotal. Commercially available COVID tests remain essential tools in maintaining individual and community safety.
While the pandemic’s trajectory remains uncertain, ongoing vigilance, informed booster choices, and continued testing contribute to a more informed and resilient response to the evolving circumstances.
As the world continues to grapple with the pandemic’s uncertainties, maintaining vigilance is paramount. Choosing between an immediate booster and waiting for the fall upgrade involves weighing your risk factors, exposure potential, and vaccination history. In this dynamic situation, patience, informed discussions with healthcare providers, and staying attuned to the latest updates will help you make the most suitable decision for your health and well-being.